Shengjun Xu

机构：University of Science and Technology of China, Westlake University, Hangzhou First People's Hospital, Zhejiang University · ORCID：0000-0002-1679-1885

发表论文 87 篇 · 总被引 1640 次 · h-index 23

代表论文

• The p-MYH9/USP22/HIF-1α axis promotes lenvatinib resistance and cancer stemness in hepatocellular carcinoma (2024 · Signal Transduction and Targeted Therapy · 被引 66)
• Mitochondria-Targeted Icaritin Nanoparticles Induce Immunogenic Cell Death in Hepatocellular Carcinoma (2024 · ACS Applied Materials & Interfaces · 被引 30)
• Mitochondria-targeted ROS-scavenging polymer protects the hepatocytes and macrophages against hepatic ischemia-reperfusion injury (2025 · Acta Biomaterialia · 被引 13)
• Heterogeneity and plasticity of cholangiocytes in liver injury: a journey from pathophysiology to therapeutic utility (2025 · Gut · 被引 11)
• Multi-omic analysis reveals a CAF-stemness-governed classification in HCC liver transplant recipients beyond the Milan criteria (2025 · Nature Communications · 被引 10)
• No-touch recipient hepatectomy in liver transplantation for liver malignancies: A state-of-the-art review (2024 · Hepatobiliary & pancreatic diseases international · 被引 7)